This is a routine equity compensation filing with no trading implications. The ~1.16% dilution is immaterial and typical for a clinical-stage biotech. Monitor upcoming pipeline catalysts or quarterly financial results for directional signals.
Price Chart
Executive Summary
Ascentage Pharma granted a total of 4,354,473 equity awards on June 29, 2026 under its 2021 RSU, 2022 RSU, and Post IPO Share Option schemes, representing approximately 1.16% of the company's outstanding shares. The awards are standard compensation to employees, non-executive directors, and a service provider. No financial results, pipeline updates, or business developments were disclosed in the filing.
Key Facts
- 440,743 RSUs granted to 453 employees under the 2021 RSU Scheme (0.12% of shares outstanding)
- 3,223,685 RSUs granted to 251 persons under the 2022 RSU Scheme (0.86% of shares outstanding), including directors
- 690,045 Options granted to 30 grantees under the Post IPO Share Option Scheme (0.18% of shares outstanding)
- Total potential dilution: ~4,354,473 shares or ~1.16% of current share capital
- H-share closing price on grant date: HK$33.62; option exercise price: HK$33.62 (at-the-money)
- All awards are satisfied by new share issuance under the existing Scheme Mandate Limit (10% of shares authorized at 2026 AGM)
- No cash consideration is required for RSU grants; purchase price is nil
Financial Impact
Modest non-cash compensation expense; the awards represent ~1.16% dilution of outstanding shares. The notional value at HK$33.62/share is approximately HK$146.4 million, but no cash was raised.
Risk Factors
- Modest dilution from new share issuance, though immaterial at ~1.16%
- Awards to directors and employees may signal retention needs but no evidence of distress
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-073699 |
| Document: ea0296418-6k_ascentage.htm | 0001213900-26-073699 |
| Document: 0001213900-26-073699-index-headers.html | 0001213900-26-073699 |
| Document: 0001213900-26-073699-index.html | 0001213900-26-073699 |
| Document: 0001213900-26-073699.txt | 0001213900-26-073699 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $15.44 $15.45 | ▲ +0.06% | ▼ −0.65% | $14.85 (−3.82%) |
Oct 21, 2026 6d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $14.85 (−0.47%) |
Oct 15, 2026 12d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $14.85 (+1.09%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $14.85 (+3.38%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $14.85 (+14.26%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $14.85 (−11.90%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $14.85 (−11.63%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $14.85 (−21.39%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $14.85 (−19.16%) |
Jul 13, 2026 15w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $14.85 (−22.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers